Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Payables (2016 - 2025)

Historic Payables for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $674.3 million.

  • Neurocrine Biosciences' Payables rose 4607.89% to $674.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $674.3 million, marking a year-over-year increase of 4607.89%. This contributed to the annual value of $674.3 million for FY2025, which is 4607.89% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Payables stood at $674.3 million for Q4 2025, which was up 4607.89% from $584.3 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Payables peaked at $674.3 million during Q4 2025, and registered a low of $171.9 million during Q1 2021.
  • In the last 4 years, Neurocrine Biosciences' Payables had a median value of $417.2 million in 2024 and averaged $408.1 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 2192.84% in 2024, then skyrocketed by 4879.04% in 2025.
  • Neurocrine Biosciences' Payables (Quarter) stood at $205.9 million in 2021, then surged by 117.97% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then skyrocketed by 46.08% to $674.3 million in 2025.
  • Its last three reported values are $674.3 million in Q4 2025, $584.3 million for Q3 2025, and $489.5 million during Q2 2025.